10-Q: Dyadic Reports Q2 Loss Reduction, Boosts Liquidity

Dyadic International, Inc. (DYAI) reported a reduced net loss and increased total revenue for Q2 2025, while addressing Nasdaq compliance and securing $5.3 million in post-period capital.

Summary

• Dyadic International, Inc. (now Dyadic Applied BioSolutions) reported a net loss of $3,821,353 for the six months ended June 30, 2025, a 5.8% improvement from $4,054,819 in the prior year period.
• Total revenue for the six months ended June 30, 2025, significantly increased by 88.8% to $1,360,202, up from $720,513 in the same period of 2024, driven by new grant and milestone revenues.
• Grant revenue, primarily from the Gates Foundation and CEPI, totaled $713,653 for the six months ended June 30, 2025, compared to none in the prior year.
• License and milestone revenue reached $250,000 for the six months ended June 30, 2025, related to the Inzymes Agreement.
• Loss from operations decreased by 10.5% to $3,731,543 for the six months ended June 30, 2025, compared to $4,168,149 in the prior year.
• Research and development expenses increased by 8.3% to $1,124,358 for the six months ended June 30, 2025, reflecting a rise in internal research initiatives.
• General and administrative expenses decreased by 10.7% to $3,032,968 for the six months ended June 30, 2025, due to reductions in business development, investor relations, and legal costs.
• Cash and cash equivalents decreased to $2,140,899 as of June 30, 2025, from $6,506,750 at December 31, 2024.
• Total stockholders' equity became negative at $(529,701) as of June 30, 2025, down from $2,470,290 at December 31, 2024.
• The company received Nasdaq deficiency notices on June 23, 2025, for not maintaining a minimum Market Value of Listed Securities (MVLS) of $35 million, and on July 17, 2025, for not maintaining a minimum bid price of $1.00 per share.
• Subsequent to the reporting period, on August 1, 2025, the company closed an offering of 6,052,000 shares of common stock at $0.95 per share, generating approximately $5.3 million in net proceeds.
• The company expects its combined existing liquidity and the proceeds from the recent offering to be sufficient for at least the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company shows significant revenue growth, reduced losses, and a successful capital raise, it also faces critical challenges including negative equity and Nasdaq delisting threats. The strategic shift to commercialization is promising but still in early stages, balancing potential upside with substantial execution and financial risks.

Positives

• Total revenue for the six months ended June 30, 2025, increased significantly by 88.8% to $1,360,202, compared to $720,513 in the prior year.
• The company successfully secured new grant revenue streams, including $713,653 from the Gates Foundation and CEPI for the six months ended June 30, 2025.
• License and milestone revenue of $250,000 was recognized from the Inzymes Agreement, indicating progress in commercialization efforts.
• Net loss decreased by 5.8% to $3,821,353 for the six months ended June 30, 2025, compared to $4,054,819 in the prior year.
• Loss from operations decreased by 10.5% to $3,731,543 for the six months ended June 30, 2025, reflecting improved operational efficiency.
• Net cash used in operating activities improved to $2,079,746 for the six months ended June 30, 2025, from $3,077,354 in the prior year, indicating reduced cash burn from core operations.
• General and administrative expenses decreased by 10.7% to $3,032,968, demonstrating cost management efforts.
• The company successfully completed a public offering on August 1, 2025, raising approximately $5.3 million in net proceeds, significantly bolstering its liquidity.
• Rebranding to Dyadic Applied BioSolutions signifies a strategic shift towards commercialization of non-therapeutic proteins, aiming for faster revenue generation and broader market reach.
• Significant progress in product development across multiple platforms, including expected commercial launch of dairy enzymes in late 2025 and serum albumin in 2025, and initial enzyme delivery for Fermbox Bio in Q2 2025.

Negatives

• Cash and cash equivalents decreased significantly to $2,140,899 as of June 30, 2025, from $6,506,750 at December 31, 2024.
• Total stockholders' equity became negative at $(529,701) as of June 30, 2025, down from $2,470,290 at December 31, 2024, indicating a deteriorating financial position.
• Received Nasdaq deficiency notices for failing to meet the minimum Market Value of Listed Securities ($35 million) and minimum bid price ($1.00 per share) requirements, posing a delisting risk.
• Research and development revenue decreased to $396,549 for the six months ended June 30, 2025, from $720,513 in the prior year, due to a reduction in active collaborations.
• The company continues to incur losses and expects negative net cash flows from operating activities as it develops its platforms and products.
• The recent capital raise, while necessary, involved the issuance of 6,052,000 shares at $0.95 per share, which is dilutive to existing shareholders.

Risks

• History of net losses and expectation of continued losses and negative net cash flows from operating activities.
• Uncertainty regarding market and regulatory acceptance of microbial protein production platforms and other technologies.
• Risk of failure to commercialize microbial protein production platforms or other technologies.
• Intense competition from alternative technologies and other biotechnology companies.
• Uncertainty of results from nonclinical studies and clinical trials.
• Significant capital needs to finance developmental efforts and potential inability to raise additional capital on favorable terms, if at all.
• Exposure to changes in global economic and financial conditions.
• Reliance on information technology systems and potential for disruptions.
• Dependence on third parties for research, development, manufacturing, and commercialization.
• Risks associated with government regulations and environmental, social, and governance issues.
• Intellectual property risks, including the ability to protect and enforce patents and other proprietary rights.
• Inability to comply with the listing standards of the Nasdaq Stock Market LLC, potentially leading to delisting and adverse effects on stock liquidity and price.
• Potential for dilution of existing shareholders if future capital raises involve equity offerings.

Future Outlook

The company expects to incur losses and negative net cash flows from operating activities as it continues to develop its microbial protein production platforms and products. However, with existing cash, cash equivalents, restricted cash, short-term investment securities totaling approximately $6.9 million as of June 30, 2025, combined with the $5.3 million net proceeds from the August 2025 offering, the company anticipates sufficient liquidity to meet operational and business requirements for at least the next twelve months. The company is actively pursuing commercialization of Dapibus-enabled products starting in 2025 and continues to explore partnering opportunities for its C1 platform in pharmaceutical development.

Management Comments

• "This rebranding initiative marks a strategic transition from a research-driven organization to a commercially focused enterprise."
• "The new name and visual identity better reflect the emphasis on delivering applied biotechnology solutions through our patented and proprietary C1 and Dapibus gene expression platforms."
• "These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics, enabling faster time to revenue, broader market reach, and long-term supply agreements."
• "Our recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, such as with the Gates Foundation, underscore our strategic shift to revenue-focused bioprocessing protein platforms from therapeutic and vaccine development."
• "The Company expects its existing cash, cash equivalents, restricted cash and cash equivalents and its short term investment securities, totaling approximately $6.9 million as of June 30, 2025, together with the capital raised from the Offering of approximately $5.3 million, will be sufficient to meet its operational, business, and other liquidity requirements for at least the next twelve (12) months."
• "Dyadic expects to commercialize multiple Dapibus-enabled products starting in 2025 through a combination of strategic partnerships and internal manufacturing initiatives."

Industry Context

Dyadic's strategic shift to focus on non-therapeutic applications for its C1 and Dapibus platforms aligns with broader industry trends emphasizing sustainable, animal-free, and bio-based innovation in life sciences, food and nutrition, and bio-industrial sectors. This move aims to capitalize on growing demand for high-value proteins with potentially faster development timelines and simpler regulatory pathways compared to traditional therapeutic biologics. The company's collaborations with entities like the Gates Foundation and CEPI also position it within global health initiatives for vaccine development and pandemic preparedness, leveraging its platforms for cost-effective, scalable protein production.

Comparison to Industry Standards

• Recombinant Bovine Alpha-Lactalbumin product shows comparability to commercial benchmarks.
• Recombinant Transferrin demonstrated equivalent performance to leading recombinant standards.
• Dyadic's C1 microbial expression technology is expected to be among the platform technologies evaluated by the European Vaccines Hub for Pandemic Readiness (EVH), highlighting its potential to accelerate development and reduce manufacturing costs compared to traditional systems like CHO, yeast, and insect cell systems.
• C1 Host Cell Protein (HCP) ELISA Kit, developed with Cygnus Technologies (Maravai LifeSciences), supports C1/Dapibus regulatory workflows, indicating a focus on industry-standard compliance and validation.

Corporate Governance

Legal Proceedings

• Not currently involved in any litigation believed to have a materially adverse effect on financial condition or results of operations.
• Subject to legal proceedings, asserted claims, and investigations in the ordinary course of business, which management considers immaterial individually and in the aggregate.

Related Party Transactions

• On March 8, 2024, the company issued $2.0 million of its $6.0 million Senior Secured Convertible Promissory Notes to related parties, including immediate family members and family trusts related to Mark Emalfarb, the President and CEO.
• As of June 30, 2025, $1,090,000 of the Convertible Notes Related Party principal remained outstanding, with $21,800 in accrued interest to related parties.

Stakeholder Impact

• **Shareholders**: Potential for dilution from the recent $5.3 million equity offering. Risk of delisting from Nasdaq could negatively impact stock liquidity and market price. Negative stockholders' equity indicates a challenging financial position.
• **Employees**: Continued R&D activities and strategic shift may offer new opportunities, but ongoing losses and capital needs could create uncertainty.
• **Customers/Partners**: Rebranding to Dyadic Applied BioSolutions and focus on commercialization aims to strengthen relationships and deliver applied biotechnology solutions. New grants and collaborations (Gates Foundation, CEPI, Proliant, Inzymes, Fermbox Bio) indicate continued engagement and potential for new product offerings.
• **Creditors**: Convertible notes are senior secured obligations, providing some protection. The recent capital raise improves the company's ability to meet short-term obligations.
• **Regulatory Bodies**: Nasdaq deficiency notices require active monitoring and evaluation of options to regain compliance, impacting the company's standing with regulatory authorities.

Next Steps

• Regain compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement by December 20, 2025.
• Regain compliance with Nasdaq's minimum bid price requirement by January 13, 2026.
• Commercialize multiple Dapibus-enabled products starting in 2025 through strategic partnerships and internal manufacturing initiatives.
• Receive a final payment of $500,000 from Proliant in Q3 2025 upon meeting a certain productivity threshold.
• Initiate sampling for Recombinant Human Lactoferrin in Q3 2025.
• Continue optimization of RNA/DNA Toolkit enzymes into late 2025 and 2026.
• Complete production validation and expect a research-grade DNase-1 (RNase-free) product by the end of 2025.
• Continue to evaluate licensing, collaboration, and commercialization opportunities for the C1 platform in the biologics sector.
• Continue to develop its C1 fungal expression system with VTT Technical Research Centre of Finland Ltd. until September 30, 2025.

Key Dates

Recommendation

The company is in a critical transition phase, marked by a strategic rebranding towards commercialization and significant revenue growth from new grants and milestone payments. The recent $5.3 million capital raise provides a much-needed liquidity boost, addressing immediate going concern risks. However, the company still faces substantial challenges, including negative stockholders' equity, continued operating losses, and Nasdaq deficiency notices that pose a delisting threat. While the long-term potential of its C1 and Dapibus platforms in non-therapeutic markets is promising, the execution risks and financial instability warrant a cautious 'hold' recommendation. Investors should monitor progress on commercialization, Nasdaq compliance, and sustained improvements in financial health.

Keywords

Biotechnology, Protein Production, C1 Platform, Dapibus Platform, SEC Filing, 10-Q, Financial Results, Nasdaq Compliance, Capital Raise, Biologics, Vaccines, Therapeutics, Food & Nutrition, Life Sciences, Bio-Industrial, Grants, Research & Development, Commercialization